论文部分内容阅读
目的:观察新加阳和汤治疗强直性脊柱炎的临床疗效。方法:选取40例患者,随机分为治疗组和对照组各20例:治疗组予新加阳和汤,对照组予塞来昔布和柳氮磺胺吡啶。分别观察两组治疗前、治疗4周及8周时患者NBP、TBP、PGDA、BASDAI、BASFI、BASMI评分及不良反应,并以强直性脊柱炎评估指标ASAS20作为临床疗效标准。结果:治疗8周后,治疗组总有效率90.00%,略高于对照组85.00%;2组均能明显降低NBP、TBP、PGDA、BASDAI、BASFI、BASMI评分;治疗组未出现不良反应,对照组出现5例。结论:新加阳和汤在强直性脊柱炎患者的近期治疗中疗效确切,且无不良反应。
Objective: To observe the clinical efficacy of Xin Yang Decoction in treating ankylosing spondylitis. Methods: Forty patients were randomly divided into treatment group (n = 20) and control group (n = 20). The treatment group was added with Yanghe Decoction and the control group with celecoxib and sulfasalazine. The NBP, TBP, PGDA, BASDAI, BASFI, BASMI scores and adverse reactions in two groups were observed before treatment, 4 weeks and 8 weeks respectively. ASAS20 was used as the standard of clinical curative effect. Results: After 8 weeks of treatment, the total effective rate in the treatment group was 90.00%, slightly higher than that in the control group (85.00%). The NBP, TBP, PGDA, BASDAI, BASFI and BASMI scores of the two groups were significantly lower than those of the control group Group appeared in 5 cases. Conclusion: Xinjiangyang Decoction is effective in the short-term treatment of patients with ankylosing spondylitis and has no adverse reactions.